273 related articles for article (PubMed ID: 24666832)
1. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
2. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
3. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
5. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
7. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
8. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
9. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
10. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
11. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
12. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
13. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
15. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
[TBL] [Abstract][Full Text] [Related]
16. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Johnson SL; Klapper PE; Vallely PJ; Picton ML
Am J Transplant; 2014 Jul; 14(7):1619-29. PubMed ID: 24815922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]